Stock AnalizBiomarin Pharmaceutical (BMRN) earnings for the quarter ended September 2026: EPS beats estimates
Biomarin Pharmaceutical reported results for the quarter ended September 2026 on November 2, 2026. Adjusted earnings per share came in at $0.23 against the analysts’ average forecast of -$0.11, a beat of 304.8%.
Revenue for the quarter was $1.02 billion, up 32.0% from $776 million in the same quarter a year earlier.
The market’s verdict: the stock fell 1.1% on the first trading day after the report.
The last four quarters
Biomarin Pharmaceutical has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.23 | -$0.11 | +304.8% | +32% | −1.1% |
| Jun 2026 | $1.20 | $0.95 | +25.8% | +20% | +6.5% |
| Mar 2026 | $0.76 | $0.91 | −16.9% | +3% | −1.5% |
| Dec 2025 | $0.46 | $0.56 | −17.9% | +17% | −2.3% |
What comes next
Analysts expect EPS of $0.89 for the next quarter on average and $3.03 for the fiscal year ending December 31, 2026.
The average analyst price target is $90.78, 59% above the current price of $57.23.
Valuation and score
Biomarin Pharmaceutical scores 2.0 out of 5 overall on Stock Analiz (average), and its intrinsic value under moderate assumptions is about 12% below the current market value. Full Biomarin Pharmaceutical analysis with 10 years of financials
Frequently asked questions
What was Biomarin Pharmaceutical’s EPS for the quarter ended September 2026?
$0.23 adjusted per share, against an analyst consensus of -$0.11.
How much revenue did Biomarin Pharmaceutical report?
$1.02 billion, up 32.0% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.